Braveheart Bio Targets $1.2 Billion Valuation in IPO
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
Archive
The heart-disease drug developer is seeking up to $318.8 million for clinical trials and research.
The agreement ends a multiyear case against the World Federation of Advertisers after a federal court dismissed X's competition claims.
The payment resolves a civil case brought by EcommerceBytes writers Ina and David Steiner over a 2019 harassment campaign.
The Claude developer moved ahead of OpenAI as frontier AI companies prepare for public scrutiny.
The startup's team will join Meta's effort to develop AI systems for humanoid robots.
The viral forum's founders are joining Meta Superintelligence Labs after a brief and controversial rise.
The open-source testing company will strengthen security evaluation for enterprise agents in OpenAI Frontier.
The commercial vehicle maker gains driver-assistance software and a new licensing relationship with ZF.
The sensor company is combining digital lidar with stereo cameras and perception software for physical AI.
The all-stock transaction brings rockets, satellites, social media and artificial intelligence under one company.